LLY

1,019.16

+2.69%↑

JNJ

210.09

+2.68%↑

ABBV

222.92

-0.29%↓

UNH

339.07

+4.39%↑

AZN

90.72

+0.2%↑

LLY

1,019.16

+2.69%↑

JNJ

210.09

+2.68%↑

ABBV

222.92

-0.29%↓

UNH

339.07

+4.39%↑

AZN

90.72

+0.2%↑

LLY

1,019.16

+2.69%↑

JNJ

210.09

+2.68%↑

ABBV

222.92

-0.29%↓

UNH

339.07

+4.39%↑

AZN

90.72

+0.2%↑

LLY

1,019.16

+2.69%↑

JNJ

210.09

+2.68%↑

ABBV

222.92

-0.29%↓

UNH

339.07

+4.39%↑

AZN

90.72

+0.2%↑

LLY

1,019.16

+2.69%↑

JNJ

210.09

+2.68%↑

ABBV

222.92

-0.29%↓

UNH

339.07

+4.39%↑

AZN

90.72

+0.2%↑

Home・Aktien・Vivani Medical

Vivani Medical

Open

1.43 -7.14

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.42

Max

1.54

Schlüsselkennzahlen
By Trading Economics
Angestellte	37

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+170.27% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-6.9M 97M
Vorheriger Eröffnungskurs	8.57
Vorheriger Schlusskurs	1.43

Vivani Medical Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Dez. 2025, 22:02 UTC

Ergebnisse

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10. Dez. 2025, 21:46 UTC

Ergebnisse

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10. Dez. 2025, 23:52 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10. Dez. 2025, 23:43 UTC

Market Talk

Nikkei May Rise After Fed Rate Cut -- Market Talk

10. Dez. 2025, 23:36 UTC

Market Talk

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10. Dez. 2025, 23:20 UTC

Ergebnisse

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10. Dez. 2025, 23:15 UTC

Ergebnisse

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10. Dez. 2025, 22:59 UTC

Market Talk

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10. Dez. 2025, 22:45 UTC

Market Talk

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10. Dez. 2025, 22:40 UTC

Ergebnisse

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10. Dez. 2025, 22:06 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10. Dez. 2025, 22:06 UTC

Ergebnisse

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10. Dez. 2025, 22:02 UTC

Ergebnisse

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10. Dez. 2025, 22:00 UTC

Ergebnisse

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10. Dez. 2025, 21:53 UTC

Ergebnisse

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10. Dez. 2025, 21:50 UTC

Akquisitionen, Fusionen, Übernahmen

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10. Dez. 2025, 21:50 UTC

Market Talk

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Financial Services Roundup: Market Talk

10. Dez. 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

10. Dez. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

10. Dez. 2025, 21:45 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10. Dez. 2025, 21:33 UTC

Ergebnisse

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10. Dez. 2025, 21:32 UTC

Ergebnisse

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10. Dez. 2025, 21:28 UTC

Akquisitionen, Fusionen, Übernahmen

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10. Dez. 2025, 21:25 UTC

Ergebnisse

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10. Dez. 2025, 21:18 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10. Dez. 2025, 21:16 UTC

Ergebnisse

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10. Dez. 2025, 21:15 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10. Dez. 2025, 21:15 UTC

Ergebnisse

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10. Dez. 2025, 21:14 UTC

Ergebnisse

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10. Dez. 2025, 21:14 UTC

Ergebnisse

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Peer-Vergleich

Kursveränderung

Vivani Medical Prognose

Kursziel

By TipRanks

170.27% Vorteil

12-Monats-Prognose

Durchschnitt 4 USD 170.27%

Hoch 4 USD

Tief 4 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Vivani Medical – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

Buy

Halten

Sell

Basierend auf 2 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Vivani Medical – Dist abgegeben haben.

Finanzen

Über Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.